| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023894 |
| Receipt No. | R000027521 |
| Official scientific title of the study | The verification study for blood lipid reduction effects: a randomized, double-blind, controlled trial |
| Date of disclosure of the study information | 2016/09/01 |
| Last modified on | 2017/05/02 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | The verification study for blood lipid reduction effects: a randomized, double-blind, controlled trial | |
| Title of the study (Brief title) | The verification study for blood lipid reduction effects | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the LDL-cholesterol reduction effects due to the ingestion of the test material. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. LDL-cholesterol
*1 Take the blood samples at 0 week and 12 weeks after the ingestion |
| Key secondary outcomes | 1. Total cholesterol, HDL-cholesterol, LDL/HDL ratio, triglyceride (TG), glucose, HbA1c, and glycoalbumin
*1 Take the blood samples at 0 week and 12 weeks after the ingestion 2. Body weight, BMI, and body fat percentage *2 Take the measurements at 0 week and 12 weeks after the ingestion |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 12 weeks
Test material: "health beverage" Administration: Drink it at any time of a day |
|
| Interventions/Control_2 | Duration: 12 weeks
Test material: "Placebo beverage" Administration: Drink it at any time of a day |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy Japanese adults of 20 years old or more
2. LDL-cholesterol levels were higher in the boundary region at most recent medical check-up |
|||
| Key exclusion criteria | 1. At least one previous medical history of malignant tumor, heart failure or myocardial infarction
2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases 3. Currently taking medicines and/or herbal medicines 4. Those who eat Food with Functional Claims of the LDL-cholesterol reduction effects and drink beverage with related to vinegar on a daily basis 5. Those who eat and/or drink Food for Specified Health Uses and/or Food with Function Claims on a daily basis 6. Allergic to medicines or foods related to the test food of this trial 7. Pregnant, lactating, or planning to get pregnant during the trial period 8. Enrolled into other clinical trials within the last 3 months before agreeing to participate in this trial 9. Judged unsuitable for participating in this trial by physician |
|||
| Target sample size | 14 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuo YAMAMOTO |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| kazu@orthomedico.jp | |
| Public contact | |
| Name of contact person | Naoko SUZUKI |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| Homepage URL | |
| nao@orthomedico.jp | |
| Sponsor | |
| Institute | ORTHOMEDICO, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Fukuyama Kurozu Inc.. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Seishin-kai Medical Association Inc, Takara Medical Clinic. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団 盛心会 タカラクリニック (東京都)
Seishin-kai Medical Association Inc, Takara Medical Clinic (Tokyo) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027521 |